SLC22A12 and metabolic disease: As PPARγ activation beneficially affects chronic inflammatory diseases such as rheumatoid arthritis, and as gout is closely associated with metabolic diseases, lesinurad’s PPARγ modulation appears as supportive side-activity to its URAT1 inhibitory potency.